These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 9376577

  • 1. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
    Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M.
    Blood; 1997 Oct 15; 90(8):2969-77. PubMed ID: 9376577
    [Abstract] [Full Text] [Related]

  • 2. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M.
    Cytokines Mol Ther; 1995 Mar 15; 1(1):21-8. PubMed ID: 9384660
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
    Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, Germing U.
    Leuk Res; 2003 May 15; 27(5):397-404. PubMed ID: 12620291
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
    Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, MacKie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP.
    Br J Haematol; 2001 Jan 15; 112(1):127-37. PubMed ID: 11167793
    [Abstract] [Full Text] [Related]

  • 11. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, Nakamura Y, Arai Y, Tadokoro J, Handa T, Tsurumi S, Arai H, Kawagoe Y, Gunnji H, Kitsukawa Y, Takahashi W, Furusawa S.
    Int J Hematol; 2000 Apr 15; 71(3):238-44. PubMed ID: 10846828
    [Abstract] [Full Text] [Related]

  • 12. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB.
    Estey EH, Shen Y, Thall PF.
    Blood; 2000 Jan 01; 95(1):72-7. PubMed ID: 10607687
    [Abstract] [Full Text] [Related]

  • 13. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 01; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 14. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal.
    Breccia M, Latagliata R, Cannella L, Carmosino I, De Cuia R, Frustaci A, Stefanizzi C, Santopietro M, Alimena G.
    Leuk Res; 2009 Mar 01; 33(3):391-4. PubMed ID: 18676015
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids.
    Estey EH.
    Leukemia; 1998 Sep 01; 12 Suppl 1():S13-5. PubMed ID: 9777888
    [Abstract] [Full Text] [Related]

  • 19. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
    Huh YO, Jilani I, Estey E, Giles F, Kantarjian H, Freireich E, Albitar M.
    Leukemia; 2002 Nov 01; 16(11):2249-52. PubMed ID: 12399969
    [Abstract] [Full Text] [Related]

  • 20. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
    Tavernier E, Le QH, Elhamri M, Thomas X.
    Leuk Res; 2003 Mar 01; 27(3):205-14. PubMed ID: 12537972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.